• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Oseltamivir and the risk of neuropsychiatric events: a national, population-based study

tetano

Editor, Senior Moderator
Clin Infect Dis. 2020 Jan 30. pii: ciaa055. doi: 10.1093/cid/ciaa055. [Epub ahead of print] [h=1]Oseltamivir and the risk of neuropsychiatric events: a national, population-based study.[/h]
Huh K[SUP]1[/SUP], Kang M[SUP]2[/SUP], Shin DH[SUP]3[/SUP], Hong J[SUP]2[/SUP], Jung J[SUP]2,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Reports of serious neuropsychiatric events (NPEs), specifically suicide/suicide attempts following the use of oseltamivir, have led to public concerns. This study aimed to determine whether an association exists between oseltamivir use and neuropsychiatric events.
[h=4]METHOD:[/h] This study was a population-based retrospective cohort study on a random sample of 50% of individuals in the Korean National Health Insurance Service (KNIS) database aged ≥8 years who were diagnosed with influenza from 2009 to 2017. The primary exposure was oseltamivir prescription at the time of influenza diagnosis, whereas the primary outcome was a diagnosis of an NPE within 30 days after the influenza diagnosis. Information on oseltamivir prescription, diagnoses of NPEs, demographic characteristics, comorbidities, drugs prescribed within the year before influenza diagnosis, and healthcare utilization were extracted from the KNIS database.
[h=4]RESULTS:[/h] Of 3,352,015 individuals included in the analysis, 1,266,780 (37.8%) were prescribed oseltamivir. The incidence of NPEs was 0.86% and 1.16% in patients who were and were not prescribed oseltamivir, respectively (hazard ratio
: 0.74, 95% confidence interval [CI]: 0.73-0.75, P<0.001). Oseltamivir use was not associated with a difference in the overall risk of NPEs in the adjusted model (HR: 0.98, 95% CI: 0.96-1.01, P=0.16), but the incidence of moderate-to-severe NPEs was significantly lower in those prescribed oseltamivir (HR: 0.92, 95% CI: 0.88-0.96, P<0.001).
[h=4]CONCLUSION:[/h] Treating influenza with oseltamivir does not increase the risk of NPEs; thus, public concern regarding its use is unwarranted.
? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.


[h=4]KEYWORDS:[/h] influenza; neuropsychiatric events; oseltamivir

PMID: 31996920 DOI: 10.1093/cid/ciaa055
 
Back
Top Bottom